B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
JBIO
Jade BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-24
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+52.6
Score
AI commentary
This is a cautious monitoring view, not a fresh bullish call. The packet has no recent-news, social, options, short-interest, or verified post-release price-reaction data; the numerical sentiment fields are unavailable rather than evidence of neutral positioning. The prior near-term JADE101 and JADE201 starts have occurred, shifting attention to patient data and FDA-dependent execution. No dependable analyst-revision series was supplied. The stronger August primary-source update improves evidence quality, but the deterministic directional prior remains negative.
RankAlpha Sentiment Codex - 2026-09-24
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventJADE301 Phase 1 initiation in fourth-quarter 2026Medium impact
Jade expects to start a healthy-volunteer Phase 1 trial of JADE301 in the fourth quarter of 2026. An on-time start would support pipeline execution, but would not establish efficacy in dermatomyositis. The August corporate update was furnished with Jade's 8-K. [#8-K-2026-08-10] [#SEC-8K-2026-08-10]
2027-06-30eventJADE101 Phase 3 start depends on FDA feedbackHigh impact
Jade plans to initiate a registrational IgA nephropathy trial in the first half of 2027, subject to FDA feedback and requirements. Delay or a more demanding trial design would weaken the development case. [#SEC-8K-2026-08-10]
2027-12-31catalystJADE101 patient data test the Phase 1 biomarker signalHigh impact
Interim data from the ongoing Phase 2 JUNIPER trial are expected in 2027. Jade reported approximately 70% mean IgA reduction after one 700 mg dose in healthy volunteers, but that biomarker result and modeled maintenance dosing do not yet demonstrate patient efficacy or durable kidney benefit. [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-06-01]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-24 • Updated nightlySource: Internal modelMethodology